Tebufelone

TargetMol
Product Code: TAR-T68155
Supplier: TargetMol
CodeSizePrice
TAR-T68155-1mg1mg£140.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68155-1mL1 mL * 10 mM (in DMSO)£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68155-5mg5mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68155-10mg10mg£308.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68155-25mg25mg£477.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68155-50mg50mg£661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68155-100mg100mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68155-500mg500mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C

Images

1 / 1

Further Information

Bioactivity:
Tebufelone is a potent in vitro inhibitor of CO , a novel non-steroidal anti-inflammatory drug (NSAID) belonging to the di-tert-butylphenol (DTBP) class that has shown potent anti-inflammatory, analgesic and anti-reticulitis properties in various animal models. Tebufelone potently inhibits the formation of prostaglandins (PGE2) and blocks the formation of lipoxygenase pathway products [leukotriene (LTB4)] in rat macrophages (IC50 = 20 microM) and human whole blood (IC50 = 22 microM) in vitro. = 20 microM) and human whole blood (IC50 = 22 microM) from the formation of lipoxygenase pathway products [leukotriene (LTB4)] in vitro.
CAS:
112018-00-5
Formula:
C20H28O2
Molecular Weight:
300.44
Pathway:
Immunology/Inflammation|GPCR/G Protein
Purity:
0.9952
SMILES:
O=C(C=1C=C(C(O)=C(C1)C(C)(C)C)C(C)(C)C)CCCC#C
Target:
Prostaglandin Receptor|LTR

References

Powell JH, et al. Antipyretic activity of tebufelone (NE-11740) in man. Agents Actions Suppl. 1991 ; 32:45-49. Kaffenberger RM, et al. Determination of tebufelone (a new anti-inflammatory drug) strength and stability in bulk drug, dosage formulations and feed admixtures by reversed-phase high-performance liquid chromatography. J Chromatogr. 1990 ; 505(2):349-356. Sietsema WK, et al. Absorption, bioavailability, and pharmacokinetics of tebufelone in the rat. J Pharm Sci. 1993 ; 82(6):610-612. Doyle MJ, et al. Comparison of tebufelone distribution in rat blood plasma and inflamed and noninflamed tissues following peroral and intravenous administration. J Pharm Sci. 1993 ; 82(8):847-850. Smith BJ, et al. Characterization of the effects of tebufelone on hepatic cytochromes P450 in the beagle dog. Drug Metab Dispos. 1996 ; 24(5):523-528.